Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the pancreas
• * Metastatic disease
• Unidimensionally measurable disease outside of the pancreas
• * At least 1 lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
• Must have received 1, and only 1, prior gemcitabine-containing regimen for metastatic disease unless disease has recurred within 6 months after treatment with neoadjuvant or adjuvant gemcitabine-containing therapy
• No brain metastases
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-1
• Life expectancy
• Not specified
• Hematopoietic
• WBC at least 3,000/mm\^3
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hemoglobin at least 9.0 g/dL (transfusion allowed)
• No bleeding diathesis or coagulopathy
• Hepatic
• Bilirubin no greater than upper limit of normal (ULN)
• AST and ALT no greater than 1.5 times ULN
• INR no greater than ULN
• PTT no greater than ULN
• Renal
• Creatinine no greater than 2.0 mg/dL
• No clinically significant renal impairment
• Urine protein:creatinine ratio ≥ 1.0
• Cardiovascular
• No prior myocardial infarction
• No prior stroke
• No clinically significant cardiovascular disease
• No uncontrolled hypertension (i.e., blood pressure greater than 160/110 mm Hg on medication)
• No unstable angina
• No New York Heart Association class II-IV congestive heart failure
• No serious cardiac dysrhythmia requiring medication
• No peripheral vascular disease
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No history or evidence of CNS disease (e.g, primary brain tumor or seizures not controlled with standard medical therapy)
• No other medical condition that would preclude study participation
• No psychiatric condition that would preclude study participation
• No other prior or concurrent malignancy that would preclude study participation
• No significant traumatic injury within the past 28 days
• No serious, nonhealing wound, ulcer, or bone fracture
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent prophylactic granulocyte or platelet growth factors
• Chemotherapy
• See Disease Characteristics
• More than 4 weeks since prior chemotherapy
• Endocrine therapy
• Not specified
• Radiotherapy
• At least 4 weeks since prior radiotherapy
• Surgery
• More than 7 days since prior fine needle aspirations or core biopsies
• More than 28 days since prior surgery (except closed biopsy or access port placement)
• More than 28 days since prior open biopsy
• No concurrent surgery
• Other
• More than 4 weeks since prior experimental drug study participation
• More than 4 weeks since prior investigational drugs
• No other concurrent experimental drug study participation